Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.17
-0.0300-2.50%
Post-market: 1.200.0294+2.51%16:23 EDT
Volume:2.14M
Turnover:2.54M
Market Cap:231.89M
PE:-1.45
High:1.22
Open:1.18
Low:1.16
Close:1.20
Loading ...

Esperion Therapeutics Inc - Confirms Sufficient Data to Advance to Phase 3 Studies

THOMSON REUTERS
·
20 Mar

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

GlobeNewswire
·
20 Mar

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Zacks
·
05 Mar

Q4 2024 Esperion Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

Esperion Therapeutics Reports Strong Revenue Growth in 2024

TIPRANKS
·
05 Mar

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

Esperion Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
04 Mar

Esperion Therapeutics Shares Rise on 4Q Revenue Growth

Dow Jones
·
04 Mar

Esperion Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
04 Mar

Esperion Expects Full Year 2025 Operating Expenses Of $215M-$235M, Including Approximately $15M In Non-cash Expenses Related To Stock Compensation

Benzinga
·
04 Mar

Esperion Therapeutics Q4 2024 GAAP EPS $(0.11) Beats $(0.16) Estimate, Sales $69.11M Beat $61.58M Estimate

Benzinga
·
04 Mar

BRIEF-Esperion Therapeutics Q4 Basic EPS USD -0.11

Reuters
·
04 Mar

Esperion Therapeutics Q4 Net Income USD -21.318 Million

THOMSON REUTERS
·
04 Mar

Esperion Therapeutics Inc - Q4 Total Revenue Grew 114% to $69.1 Million

THOMSON REUTERS
·
04 Mar

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
04 Mar

Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET

TIPRANKS
·
03 Mar

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

GlobeNewswire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

Insider Monkey
·
01 Mar